EGenesis focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs.
EGenesis operates as a biotechnology company. The Company focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs. eGenesis serves patients worldwide.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 2, 2021 | Series C | $125M | 1 | — | — | Detail |
Nov 7, 2019 | Series B | $100M | 2 | — | — | Detail |
Mar 16, 2017 | Series A | $38M | 2 | ARCH Venture Partners | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ARCH Venture Partners | — | Series C |
Bayer | — | Series B |
Fan Ventures | — | Series A |